Peter specialises in IP litigation, advising clients on complex disputes across a diverse range of technologies.

He advises on a wide range of contentious IP matters, including patent, trade mark, design right and copyright disputes. He has extensive experience in handling complex and high value patent litigation before the UK courts. His cases are commonly international in nature, and he often works with legal advisers from across Europe, North America and Japan, contributing to and often co-ordinating multi-jurisdictional patent litigation strategies.

Peter’s scientific background provides him with a firm understanding of technical issues. He is experienced in working with a diverse range of technologies, including pharmaceutical products and formulations, biotechnology, medical devices, telecommunications and engineering. 

Peter has particular experience in providing freedom-to-operate advice to pharmaceutical companies in relation to patent matters and advising on SPC filing strategies, notably where such applications are contested. He is also experienced in advising telecommunications companies in relation to patent and FRAND issues, having been involved in a number of the leading UK cases in this sector. He also spent six months seconded to the legal department of a global IT company.

Peter joined Powell Gilbert as an associate in 2009 and became a partner in 2016.

Key cases

  • Mylan v Sandoz (protein purification)

  • Unwired Planet v Huawei & Others (telecommunications/FRAND licensing)

  • Varian v Elekta (radiotherapy devices)

  • Teva v Actavis (rasagiline)

  • Icahn School of Medicine at Mount Sinai (SPCs - agalsidase beta)

  • TCT v Ericsson (telecommunications)

  • Corma v Hegler Plastik (extruded plastics)

  • Eugen Seitz v KHS Corpoplast and Norgren (PET plastic technology)

  • HTC v Apple (smartphones)

  • Apple v Nokia (smartphones)

  • Mölnlycke v BSN Medical (wound dressings)

  • Alan Nuttall v Fri-Jado (hot food merchandisers)

  • Teva v Aventis (docetaxel formulations) 

  • Roche v Chiron (SPCs - trastuzumab and enfuvirtide)